Esketamine and Magnesium sulfate

PreclinicalSmall molecule

TThe Second People's Hospital of Huai'an

Esketamine and Magnesium sulfate is one of 3 small molecule programs targeting Fatigue. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Laparoscopic CholecystectomyCompleted

Laparoscopic CholecystectomyPreclinical

Completed

Competition

Competitive Landscape

3 competitors in Laparoscopic Cholecystectomy

#DrugCompanyPhaseTrials

Epsom Salt

FFresenius Kabi Oncology Ltd.

Preclinical

6 2

Spravato

WWim Janssens

Preclinical

1 3

Esketamine and Magnesium sulfate

TThe Second People's Hospital of Huai'an

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Laparoscopic Cholecystectomy1 trial

Effects of Perioperative Intravenous Infusion Esketamine Combined With Magnesium Sulfate for Postoperative Fatigue Syndrome in Patients Undergoing Laparoscopic Cholecystectomy: A 2×2 Factorial Randomized Controlled Trial

Completed·TThe Second People's Hospital of Huai'an·Preclinical·NCT07131033·120 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Esketamine and Magnesium sulfate. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Esketamine and Magnesium sulfate compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Esketamine and Magnesium sulfate. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — The Second People's Hospital of Huai'an company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: TThe Second People's Hospital of Huai'an

Esketamine and Magnesium sulfate

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Laparoscopic Cholecystectomy1 trial

References

Drug Info

Quick Facts

Related News